FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

<i>N</i> ashington,	D.C.	20549

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL											
OMB Number:	3235-0287										
Estimated average burden											
hours por response.	0.5										

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

l	AN NOU		(Middle)		On 3. Da	2. Issuer Name and Ticker or Trading Symbol Omega Therapeutics, Inc. [ OMGA ]  3. Date of Earliest Transaction (Month/Day/Year) 06/07/2023								Relationship neck all appl X Direct Office below	cable) or (give title	g Per	,	/ner
C/O OMEGA THERAPEUTICS, INC.				4. If <i>i</i>	If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)					
140 FIRST STREET, SUITE 501														e) X Form filed by One Reporting Person				
(Street)	IDGE M	Α	02141											Form Perso		e than One Reporting		rting
- VEI-FI						Rule 10b5-1(c) Transaction Indication												
(City)	(S	tate)	(Zip)		Check this box to indicate that a transaction was made pursual							ion or written	plan t	that is intende	ed to			
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																	
		Iabi	le I - Noi			_			<del>-</del>	oisp					1			
1. Title of Security (Instr. 3) 2. Transac Date (Month/Da					Execution Date,			Transaction Disposed Code (Instr. 5)		rities Acquired (A) o ed Of (D) (Instr. 3, 4		Benefic Owned	es For ally (D) Following (I) (	Form (D) o	m: Direct or Indirect Instr. 4)	7. Nature of Indirect Beneficial Ownership		
								Code	v	Amount	(A) o	Price	Reporte Transac (Instr. 3	tion(s)			(Instr. 4)	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Conversion Date Security or Exercise (Month/Day/Year) If any				ransaction of ode (Instr. Derivative			Expiration Date (Month/Day/Year) S			7. Title and Amount of Securities Underlying Derivative Securit (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
					Code	٧	(A)	(D)	Date Exercisable		xpiration ate	Title	Amount or Number of Shares					
Stock Option (Right to Buy)	\$8.39	06/07/2023			A		18,118		(1)	06	5/06/2033	Common Stock	18,118	\$0.00	18,118		D	

## **Explanation of Responses:**

1. The options vest and become exercisable on the earlier of (i) the date of the Issuer's next annual meeting of stockholders and (ii) the first anniversary of the date of grant, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such vesting date.

## Remarks:

/s/ Barbara Chan as Attorney-

in-Fact for Noubar B. Afeyan,

Ph.D.

\*\* Signature of Reporting Person Date

06/09/2023

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.